<DOC>
	<DOCNO>NCT00887068</DOCNO>
	<brief_summary>The goal clinical research study learn Vidaza ( azacitidine ) help control disease patient AML , CMML , MDS allogeneic ( donor ) stem cell transplant . The safety drug also study .</brief_summary>
	<brief_title>Controlled Study Post-transplant Azacitidine Prevention Acute Myelogenous Leukemia Myelodysplastic Syndrome Relapse ( VZ-AML-PI-0129 )</brief_title>
	<detailed_description>The Study Drug : Azacitidine design block certain gene cancer cell whose job stop function tumor-fighting gene . By block `` bad '' gene , tumor-fighting gene may able work well . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 group . - If Group 1 , receive azacitidine . - If Group 2 , receive azacitidine . Study Drug Administration : If Group 1 , receive azacitidine needle skin Days 1-5 cycle . Each cycle 28 day long . Your dose azacitidine may lower stop certain side effect develop . Study Visits : About 2 3 day cycle , doctor think need , Day 3 cycle 1 time Weeks 2 3 cycle , blood ( 4 teaspoon time ) drawn routine test . At 3 , 6 , 12 month stem cell transplant : - You complete medical history physical exam . - Blood ( 4 teaspoon time ) drawn routine test . - You bone marrow aspiration check status disease . You may come back study visit often doctor think need . While study , need stay Houston 3 month transplant ( standard stem cell transplant ) . Length Study : You study treatment 1 year ( 12 cycle azacitidine ) . You take study early experience intolerable side effect disease get bad . End-of-Treatment Visit : After complete plan treatment azacitidine , end-of-treatment visit : - You complete medical history physical exam . - Blood ( 4 teaspoon ) draw routine test . - You bone marrow aspiration check status disease . This investigational study . Azacitidine FDA approve commercially available treatment myelodysplastic syndrome . Up 246 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients diagnosis AML ( World Health Organization classification : &gt; =20 % blast bone marrow / peripheral blood ) MDS ( International Prognostic Scoring System intermediate1 high ) time allogeneic transplantation : Induction Failure , relapse disease second great remission ; patient first complete remission require 1 cycle treatment achieve remission , AML evolve MDS , follow abnormality : FLT3 mutation , deletion chromosome 5 7 , MLL gene rearrangement , equal 3 cytogenetics abnormality . Patients de novo therapyrelated MDS , CMML , AML also eligible , regardless cytogenetics molecular rearrangement . 2 . Biphenotypic Leukemia time allogeneic transplantation induction failure , relapse disease , first , second great remission . 3 . Patients must complete remission post transplant . 4 . Patient may enrol 40 100 day transplant . 5 . Age 18 75 year old . 6 . Serum creatinine &lt; 1.8 mg/dL creatinine clearance great equal 40 cc/min define CockcroftGault Equation* . . Males ( mL/min ) : ( 140age ) *IBW ( kg ) / 72* ( serum creatinine ( mg/dl ) ) b . Females ( mL/min ) :0.85* ( 140age ) *IBW ( kg ) / 72* ( serum creatinine ( mg/dl ) ) . 7 . Serum direct bilirubin &lt; 1.5 mg/dL ( unless Gilbert 's syndrome ) . 8 . SGPT &lt; /= 200 IU/ml unless related patient 's malignancy . 9 . Be able understand sign inform consent . 1 . Active uncontrolled infection . 2 . Presence uncontrolled graftversushost disease . 3 . Patients underwent allogeneic transplantation treatment graft failure . 4 . Pregnancy breastfeeding ( woman childbearing potential , female experience menarche undergone surgical sterilization postmenopausal positive serum pregnancy test . 5 . Known suspected hypersensitivity azacitidine mannitol . 6 . Patients advance malignant hepatic tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Remission</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>Allotx</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-Azacitidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
</DOC>